BiotechTube

SHR8008 + Fluconazole

Phase 3UNKNOWN
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Recurrent Vulvovaginal Candidiasis

Conditions

Recurrent Vulvovaginal Candidiasis

Trial Timeline

Sep 14, 2021 → Sep 30, 2023

NCT ID
NCT05074602

About SHR8008 + Fluconazole

SHR8008 + Fluconazole is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Recurrent Vulvovaginal Candidiasis. The current trial status is unknown. This product is registered under clinical trial identifier NCT05074602. Target conditions include Recurrent Vulvovaginal Candidiasis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT05074602Phase 3UNKNOWN

Competing Products

20 competing products in Recurrent Vulvovaginal Candidiasis

See all competitors
ProductCompanyStageHype Score
KPL-914Kiniksa PharmaceuticalsPhase 2
47
KPL-387Kiniksa PharmaceuticalsPhase 2
47
Rilonacept + PlaceboKiniksa PharmaceuticalsPhase 3
72
Enzastaurin (LY317615) + CarboplatinEli LillyPhase 1
33
Zopapogene imadenovec (Zopa)PrecigenApproved
80
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2PrecigenPhase 1/2
36
[203Pb]VMT01 + [212Pb]VMT01 + NivolumabPerspective TherapeuticsPhase 1/2
33
Ramucirumab + PembrolizumabEli LillyPhase 2
52
Gemcitabine and UFTE chemotherapyYuhanPhase 2
52
Raludotatug Deruxtecan + Carboplatin + Paclitaxel + Bevacizumab + Rescue Medication + PembrolizumabDaiichi SankyoPhase 1/2
41
Ifinatamab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab DeruxtecanDaiichi SankyoPhase 1
33
PLX3397Daiichi SankyoPhase 2
52
erlotinib + etoposideAstellas PharmaPhase 2
52
Drug Combination TherapySun PharmaceuticalPhase 2
52
Niraparib + AnlotinibSun PharmaceuticalPhase 2
52
Eribulin MesylateEisaiPre-clinical
23
Lenvatinib + EverolimusEisaiPhase 1/2
41
E7090EisaiPhase 2
52
LenvatinibEisaiPhase 2
52

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85